GG
EVFM

Gofen & Glossberg’s Evofem Biosciences, Inc. Common Stock EVFM Stock Holding History

Gofen & Glossberg’s Portfolio EVFM Stock Details EVFM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-667
Closed -$3K – 610
2022
Q1 		$3K Hold
667
– – ﹤0.01% 614
2021
Q4 		$4K Hold
667
– – ﹤0.01% 623
2021
Q3 		$7K Buy
+667
New +$8.38K ﹤0.01% 614

Other funds holding EVFM

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
FWSM
First Wilshire Securities Management Pasadena, California $444M AUM 42.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Gofen & Glossberg's EVFM Position: Q2 2022 in Review

Gofen & Glossberg sold out of Evofem Biosciences, Inc. Common Stock (EVFM) in Q2 2022, closing a stake of 667 shares — an estimated $3K sold.

Gofen & Glossberg first reported a position in EVFM in Q3 2021 and held it in 3 quarters. The position peaked at $7K in Q3 2021. 44 funds tracked by Wall St. Rank hold EVFM as of Q2 2022.

  • Gofen & Glossberg reported no remaining Evofem Biosciences, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
  • Gofen & Glossberg sold 667 Evofem Biosciences, Inc. Common Stock shares in Q2 2022, an estimated $3K.
  • Gofen & Glossberg first reported a position in Evofem Biosciences, Inc. Common Stock in Q3 2021 and held it in 3 quarters.
  • Gofen & Glossberg's Evofem Biosciences, Inc. Common Stock position peaked at $7K in Q3 2021.
  • 44 funds tracked by Wall St. Rank held Evofem Biosciences, Inc. Common Stock as of Q2 2022.

Based on Gofen & Glossberg's 13F filing for Q2 2022, filed 14 Jul 2022.